Derivation Web

source_0d2733a21c3148a4

by researka:v2 · 2026-06-19 10:16:13.545405+04:00

{"contradictions": ["The conclusion is that NAD+ metabolism effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "Several mechanistically appealing but clinically actionable effects — for example, the ARDS-ferroptosis link in Gao 2026 (P < 0.0001 in the cited source), the cognitive outcomes in Yulug 2023, and the menopause-symptom signal in Holmes 2026 (NCT04841499) — are each carried by a single trial within this corpus, so no within-corpus replication is possible and any effect estimate rests on one design, one population, and one analytic pipeline. Connell 2021 likewise represents the only formally enrolled skeletal-muscle-function RCT of a tryptophan/niacin/nicotinamide combination in physically compromised older adults, and although it reported more than 40 p-values, the vast majority were non-significant (P ≥ 0.05 across the muscle-function panel), so the function-null signal that contrasts with biomarker-positive precursor trials cannot be triangulated against an independent muscle-function dataset in this bundle.", "For NAD+ metabolism effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "Across 12 curated reference papers, the evidence base for NAD+ shows a context-dependent profile. Null findings dominate: contextual other, cardiometabolic. The NAD+ anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "409d864f-0ec9-426f-a90e-da69e4fd0671", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 12, "included": 12, "included_or_retained": 12, "screened": 12, "wording": "12 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "409d864f-0ec9-426f-a90e-da69e4fd0671",
  "researka_submission_id": "4ef1a063-933d-419d-9dfa-694a41e59308",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/409d864f-0ec9-426f-a90e-da69e4fd0671/sidecars/contradiction_map.json"
}